Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | D4774 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
inappropriate schedule of vaccine/still has not received a third dose; first dose of Twinrix on 2Oct2024 and the second dose was on 14Nov2024; This non-serious case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a 35-year-old female patient who received HAB (Twinrix) (batch number D4774, expiry date 12-SEP-2026) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On 14-NOV-2024, the patient received the 2nd dose of Twinrix. The patient did not receive the 3rd dose of Twinrix. On 14-NOV-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: first dose of Twinrix on 2Oct2024 and the second dose was on 14Nov2024). The patient experienced incomplete course of vaccination (Verbatim: inappropriate schedule of vaccine/still has not received a third dose). The outcome of the incomplete course of vaccination and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-FEB-2026 The batch number was not provided and a request for this information has been made.
TWINRIX